Error loading player: No playable sources found
AM23-MN-22-O
AM23-MN-22-O: Cellular Starting Material (CSM) Forum (Enduring)
Credits
1.5 General Continuing Education (GEN) | 1.5 Florida Lab Personnel (FLP) | 1.5 California Nurse (CN) | 1.5 California Lab Personnel (CLP)
$30
Standard Price
Members save $5
The AABB Cellular Starting Material (CSM) Forum connects diverse organizations involved in Cellular Starting Material (CSM) for biotherapies. CSM is used for a variety of novel biotherapies including cellular therapy, gene and cell therapy, and regenerative medicines. The CSM Forum explores standards development, industry, and regulatory perspectives as well as strengthening the capacity for cell collection organizations to meet current and future demand for qualification to collect CSM.
Learning Objectives
- Discuss the recent developments in standardization efforts for Cellular Starting Material (CSM) in the biotherapies ecosystem
- Explore the perspectives of CSM providers and the biotherapies industry.
- Explain current and future tools and resources available to AABB members
Moderators
Vice President, Biotherapies, AABB
Linda Barnes, DrPH, MHA, RAC, CABP(H)
Advisor, Investigator, Consultant, University of Pittsburgh
Speakers
Nicole Verdun, MD
Center for Biologics Evaluation and Research Office of Therapeutic Products, FDA
Vice President of Quality, ArsenalBio
Sr. Manager, Quality Assurance, Kite Pharma
Kevin Land, MD
Vitalant
Becky B. Cap, MBA
Sr. Vice President, Chief Operating Officer, GenCure
Robert Tressler, PhD, MS
Vice President of Laboratories, San Diego Blood Bank
Tracks
Related Products
AM23-SN-07-O: Workforce Development in Cell Processing Labs: A Comprehensive Approach to Skills Enhancement and Employee Retention (Enduring)
This session proposes a comprehensive approach to workforce development in cell processing labs, which includes obtaining the internationally recognized AABB Certified Advanced Biotherapies Professional (CABP) credential…
AM23-ST-07-O: Standardization of Post-Thaw Viability Testing Method for Cryopreserved Hematopoietic Progenitor Cells (Enduring)
Cryopreservation preserves hematopoietic progenitor cells (HPC) for future use, but the freezing and thawing processes can impact viability. To ensure sufficient viable cells for downstream applications, post-thaw viability testing is essential…
AM24-SN-24-O: Crisis in the Rural Hospital Without Access to Blood Transfusion: Innovative Strategies to Address Global Blood Deserts and the Blood D.E.S.E.R.T. Coalition (Enduring)
There is an estimated annual 102 million unit blood shortage in low-income and middle-income countries (LMICs): every single country in sub-Saharan Africa and south Asia is in deficit…
